# CUPISCO (NCT03498521)

> A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03498521
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Cancer of Unknown Primary Site
- Interventions: Alectinib; Vismodegib; Ipatasertib; Olaparib; Erlotinib; Bevacizumab; Vemurafenib; Cobimetinib; Trastuzumab Subcutaneous (SC); Pertuzumab; Atezolizumab; Carboplatin; Paclitaxel; Cisplatin; Gemcitabine; Entrectinib; Ivosidenib; Pemigatinib
- Enrollment: 529
- Primary outcome: Progression Free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 24
- YouTube: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cupisco-nct03498521

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03498521", "email": "<work email>"}; the inbox owner confirms by the emailed link.